165 related articles for article (PubMed ID: 18373208)
1. Fragment-based and classical quantitative structure-activity relationships for a series of hydrazides as antituberculosis agents.
Andrade CH; Salum Lde B; Castilho MS; Pasqualoto KF; Ferreira EI; Andricopulo AD
Mol Divers; 2008 Feb; 12(1):47-59. PubMed ID: 18373208
[TBL] [Abstract][Full Text] [Related]
2. Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives.
Pasqualoto KF; Ferreira EI; Santos-Filho OA; Hopfinger AJ
J Med Chem; 2004 Jul; 47(15):3755-64. PubMed ID: 15239654
[TBL] [Abstract][Full Text] [Related]
3. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
Martins F; Ventura C; Santos S; Viveiros M
Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from Trypanosoma cruzi.
Guido RV; Trossini GH; Castilho MS; Oliva G; Ferreira EI; Andricopulo AD
J Enzyme Inhib Med Chem; 2008 Dec; 23(6):964-73. PubMed ID: 19005945
[TBL] [Abstract][Full Text] [Related]
5. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
6. Structural and chemical basis for enhanced affinity to a series of mycobacterial thymidine monophosphate kinase inhibitors: fragment-based QSAR and QM/MM docking studies.
Bueno RV; Toledo NR; Neves BJ; Braga RC; Andrade CH
J Mol Model; 2013 Jan; 19(1):179-92. PubMed ID: 22846924
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of graphical invariants in quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
Bagchi MC; Maiti BC; Mills D; Basak SC
J Mol Model; 2004 Apr; 10(2):102-11. PubMed ID: 14691675
[TBL] [Abstract][Full Text] [Related]
8. Application of quantitative structure-activity relationships to the modeling of antitubercular compounds. 1. The hydrazide family.
Ventura C; Martins F
J Med Chem; 2008 Feb; 51(3):612-24. PubMed ID: 18176999
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
Ventura C; Latino DA; Martins F
Eur J Med Chem; 2013; 70():831-45. PubMed ID: 24246731
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
12. QSAR Studies, Synthesis and Antibacterial Assessment of New Inhibitors Against Multidrug-Resistant Mycobacterium tuberculosis.
Kovalishyn V; Brovarets V; Blagodatnyi V; Kopernyk I; Hodyna D; Chumachenko S; Shablykin O; Kozachenko O; Vovk M; Barus M; Bratenko M; Metelytsia L
Curr Drug Discov Technol; 2017; 14(1):25-38. PubMed ID: 27829331
[TBL] [Abstract][Full Text] [Related]
13. In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.
Maccari R; Ottanà R; Vigorita MG
Bioorg Med Chem Lett; 2005 May; 15(10):2509-13. PubMed ID: 15863306
[TBL] [Abstract][Full Text] [Related]
14. Insights into the permeability of drugs and drug-like molecules from MI-QSAR and HQSAR studies.
Shinde RN; Srikanth K; Sobhia ME
J Mol Model; 2012 Mar; 18(3):947-62. PubMed ID: 21638045
[TBL] [Abstract][Full Text] [Related]
15. In silico design of novel quinazoline-based compounds as potential Mycobacterium tuberculosis PknB inhibitors through 2D and 3D-QSAR, molecular dynamics simulations combined with pharmacokinetic predictions.
Hanwarinroj C; Thongdee P; Sukchit D; Taveepanich S; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
J Mol Graph Model; 2022 Sep; 115():108231. PubMed ID: 35667143
[TBL] [Abstract][Full Text] [Related]
16. Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies.
Ragno R; Marshall GR; Di Santo R; Costi R; Massa S; Rompei R; Artico M
Bioorg Med Chem; 2000 Jun; 8(6):1423-32. PubMed ID: 10896119
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy.
Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V
J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic investigation of the oxidation of hydrazides: implications for the activation of the TB drug isoniazid.
Amos RI; Gourlay BS; Yates BF; Schiesser CH; Lewis TW; Smith JA
Org Biomol Chem; 2013 Jan; 11(1):170-6. PubMed ID: 23165368
[TBL] [Abstract][Full Text] [Related]
19. Insight into the structural requirements of aminopyrimidine derivatives for good potency against both purified enzyme and whole cells of M. tuberculosis: combination of HQSAR, CoMSIA, and MD simulation studies.
Punkvang A; Hannongbua S; Saparpakorn P; Pungpo P
J Biomol Struct Dyn; 2016 May; 34(5):1079-91. PubMed ID: 26156406
[TBL] [Abstract][Full Text] [Related]
20. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
